timothy sykes logo
TSHA Jumps As Canaccord Hikes Price Target On Trial Progress Thumbnail
ADD US ONG Google News

TSHA Jumps As Canaccord Hikes Price Target On Trial Progress

MATT MONACO•UPDATED APR. 19, 2026, 11:06 AM ET
Reviewed by Jack Kellogg Fact-checked by Tim Sykes

Taysha Gene Therapies Inc. stocks have been trading up by 7.56 percent following highly positive gene therapy pipeline developments.

Candlestick Chart

Weekly Update Apr 13 – Apr 17, 2026: On Sunday, April 19, 2026 Taysha Gene Therapies Inc. stock [NASDAQ: TSHA] is trending up by 7.56%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Healthcare industry expert:

Analyst sentiment – positive

Taysha Gene Therapies (TSHA) is a high-risk, development-stage CNS gene therapy name with negligible revenue ($9.8M TTM, price-to-sales ~189x) and extreme negative margins (EBIT margin below -1,100%). Cash of ~$320M, current ratio >12x, and modest leverage (total debt/equity 0.28x) provide several years of runway at the current ~$27M quarterly burn. However, ROE of -68% and accumulated deficit (> $700M) underscore heavy value dilution risk if pivotal data fail to de-risk the pipeline.

TSHA has broken out sharply from the low-$4 range, with the weekly sequence showing a clean leg higher: consolidation at $4.40–4.70, then an impulsive move to ~$6.50. The dominant trend is strongly bullish, confirmed by higher highs/lows and expanding ranges; intraday 5‑minute candles show aggressive dip buying above $6 with elevated volume. $6.00 is now the key actionable level: as long as price holds above $6 on a closing basis, risk-reward favors long positioning.

Fundamentally, TSHA trades like a clinical-stage call option on TSHA‑102 and related AAV CNS assets. Canaccord’s target hike to $17, citing REVEAL/ASPIRE progress and 2Q26 Part A data, validates institutional confidence and places the stock at a discount to its own event-driven upside. Insider sales by the R&D head are notable but not thesis-breaking, partially offset by inducement grants. Versus biotech benchmarks, TSHA is higher risk but with superior upside optionality; near term, support sits at $6, resistance at $7.50–$8, and I view the risk-adjusted setup as positively skewed.

Quick Financial Overview

Taysha Gene Therapies Inc. is trading in an active upswing, with the recent weekly data showing a sharp move from the low $4s into the mid-$6s. The stock opened near $4.42 early in the week and closed around $6.40 by 2026/04/17, a strong percentage gain in a few days. Intraday, a 5-minute candle shows a push from about $6.10 to a $6.50 high, with a close near $6.43, signaling firm demand into strength rather than profit-taking.

Under the hood, TSHA is still a classic high-risk clinical-stage name. Revenue sits near $9.77M annually, but margins are deeply negative, with profit margins and return metrics strongly in the red. The company trades at a rich price-to-sales near 189 and price-to-book around 7.48, which tells traders that the market is paying up for the gene therapy pipeline and future potential, not current earnings power.

Balance sheet strength is a key part of the trading story. Cash and equivalents are about $319.8M against total liabilities of roughly $96.38M, driving a current ratio around 12 and a relatively low total debt-to-equity near 0.28. Operating cash flow in the latest quarter was roughly -$26.72M, and free cash flow about -$26.97M, so Taysha Gene Therapies Inc. is burning cash but has runway. For traders, that cash cushion can support ongoing REVEAL and ASPIRE trial work that underpins the Canaccord $17 price target.

More Breaking News

Conclusion

Taysha Gene Therapies Inc. now sits in a spot where the tape, the news, and the balance sheet all line up around a clear risk/reward profile. On the upside, TSHA has strong cash, advancing CNS gene therapy programs, and a fresh bullish call from Canaccord with a higher $17 target tied to REVEAL and ASPIRE progress and planned 2Q26 data. On the risk side, the company is highly unprofitable, burning tens of millions in cash per quarter, and trading at steep multiples that can compress quickly if trial news disappoints.

For short-term traders, the recent surge from the $4s to the $6s, plus intraday strength toward $6.50, marks this as a momentum name where follow-through and volume matter more than traditional value metrics. In navigating such volatile setups, discipline and adaptability are crucial; as millionaire penny stock trader and teacher Tim Sykes says, “Embrace the journey, the ups and downs; each mistake is a lesson to improve your strategy.” Insider selling by Sukumar Nagendran around 2026/04/10 adds a note of caution, but his remaining 1.14M-share stake suggests continued alignment with the long pipeline story. TSHA will likely trade around catalysts: trial updates, FDA interactions, and any shifts in analyst views. As SOFCC, the trading expert view is simple: “In names like TSHA, the edge goes to traders who respect both the upside of clinical catalysts and the downside of rich valuations, and who always let price and risk management lead their decisions.”

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

How much has this post helped you?

(0 votes, average: 0 out of 5)
Leave a reply

Spot the Next Big Runner

Click Here for a Millionaire's POV on Trading TSHA

SUBSCRIBE FOR ALERTS

JOIN 50,000+ ACTIVE TRADERS

* Results are not typical and will vary from person to person. Making money trading stocks takes time, dedication, and hard work. There are inherent risks involved with investing in the stock market, including the loss of your investment. Past performance in the market is not indicative of future results. Any investment is at your own risk. See Terms of Service here

The available research on day trading suggests that most active traders lose money. Fees and overtrading are major contributors to these losses.

A 2000 study called “Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors” evaluated 66,465 U.S. households that held stocks from 1991 to 1996. The households that traded most averaged an 11.4% annual return during a period where the overall market gained 17.9%. These lower returns were attributed to overconfidence.

A 2014 paper (revised 2019) titled “Learning Fast or Slow?” analyzed the complete transaction history of the Taiwan Stock Exchange between 1992 and 2006. It looked at the ongoing performance of day traders in this sample, and found that 97% of day traders can expect to lose money from trading, and more than 90% of all day trading volume can be traced to investors who predictably lose money. Additionally, it tied the behavior of gamblers and drivers who get more speeding tickets to overtrading, and cited studies showing that legalized gambling has an inverse effect on trading volume.

A 2019 research study (revised 2020) called “Day Trading for a Living?” observed 19,646 Brazilian futures contract traders who started day trading from 2013 to 2015, and recorded two years of their trading activity. The study authors found that 97% of traders with more than 300 days actively trading lost money, and only 1.1% earned more than the Brazilian minimum wage ($16 USD per day). They hypothesized that the greater returns shown in previous studies did not differentiate between frequent day traders and those who traded rarely, and that more frequent trading activity decreases the chance of profitability.

These studies show the wide variance of the available data on day trading profitability. One thing that seems clear from the research is that most day traders lose money .

Millionaire Media 66 W Flagler St. Ste. 900 Miami, FL 33130 United States (888) 878-3621 This is for information purposes only as Millionaire Media LLC nor Timothy Sykes is registered as a securities broker-dealer or an investment adviser. No information herein is intended as securities brokerage, investment, tax, accounting or legal advice, as an offer or solicitation of an offer to sell or buy, or as an endorsement, recommendation or sponsorship of any company, security or fund. Millionaire Media LLC and Timothy Sykes cannot and does not assess, verify or guarantee the adequacy, accuracy or completeness of any information, the suitability or profitability of any particular investment, or the potential value of any investment or informational source. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. Millionaire Media LLC and Timothy Sykes in no way warrants the solvency, financial condition, or investment advisability of any of the securities mentioned in communications or websites. In addition, Millionaire Media LLC and Timothy Sykes accepts no liability whatsoever for any direct or consequential loss arising from any use of this information. This information is not intended to be used as the sole basis of any investment decision, nor should it be construed as advice designed to meet the investment needs of any particular investor. Past performance is not necessarily indicative of future returns.

Citations for Disclaimer

Barber, Brad M. and Odean, Terrance, Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors. Available at SSRN: “Day Trading for a Living?”

Barber, Brad M. and Lee, Yi-Tsung and Liu, Yu-Jane and Odean, Terrance and Zhang, Ke, Learning Fast or Slow? (May 28, 2019). Forthcoming: Review of Asset Pricing Studies, Available at SSRN: “https://ssrn.com/abstract=2535636”

Chague, Fernando and De-Losso, Rodrigo and Giovannetti, Bruno, Day Trading for a Living? (June 11, 2020). Available at SSRN: “https://ssrn.com/abstract=3423101”